INKT
Closed
Mink Therapeutics Inc
7.3395
-0.0481 (-0.65%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 7.3876
Day's Range: 7.22 - 7.51
Send
sign up or login to leave a comment!
When Written:
1.98
Mink Therapeutics Inc. is a biotechnology company that focuses on the development of RNA-based therapeutics. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Mink Therapeutics is developing a proprietary platform technology called TRNAscan, which enables the discovery and development of novel RNA-based therapies. The company is using this technology to develop treatments for a range of diseases, including cancer, genetic disorders, and infectious diseases.
The company's lead program is focused on the development of a therapy for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and wasting. Mink Therapeutics is also developing RNA-based therapies for other genetic diseases, including Huntington's disease and cystic fibrosis.
Mink Therapeutics has raised over $40 million in funding to date, including a $35 million Series A financing round in 2019. The company has partnerships with leading academic institutions, including the Broad Institute of MIT and Harvard and the University of California, San Francisco.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Mink Therapeutics is developing a proprietary platform technology called TRNAscan, which enables the discovery and development of novel RNA-based therapies. The company is using this technology to develop treatments for a range of diseases, including cancer, genetic disorders, and infectious diseases.
The company's lead program is focused on the development of a therapy for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and wasting. Mink Therapeutics is also developing RNA-based therapies for other genetic diseases, including Huntington's disease and cystic fibrosis.
Mink Therapeutics has raised over $40 million in funding to date, including a $35 million Series A financing round in 2019. The company has partnerships with leading academic institutions, including the Broad Institute of MIT and Harvard and the University of California, San Francisco.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
1.98
Mink Therapeutics Inc is a biotechnology company focused on developing RNA-based therapies for genetic diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Mink Therapeutics is developing a proprietary platform for the targeted delivery of RNA therapies to specific tissues and cells in the body. Their technology is based on the use of engineered exosomes, which are small vesicles that can transport RNA molecules to specific cells.
The company is currently focused on developing therapies for genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, and Huntington's disease. Mink Therapeutics has partnerships with several pharmaceutical companies, including Novartis and Takeda, to develop RNA-based therapies for a range of diseases.
Mink Therapeutics has raised over $80 million in funding from investors including Atlas Venture, F-Prime Capital, and GV (formerly Google Ventures). The company is led by CEO Paul Wotton, who has over 25 years of experience in the biotechnology industry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Mink Therapeutics is developing a proprietary platform for the targeted delivery of RNA therapies to specific tissues and cells in the body. Their technology is based on the use of engineered exosomes, which are small vesicles that can transport RNA molecules to specific cells.
The company is currently focused on developing therapies for genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, and Huntington's disease. Mink Therapeutics has partnerships with several pharmaceutical companies, including Novartis and Takeda, to develop RNA-based therapies for a range of diseases.
Mink Therapeutics has raised over $80 million in funding from investors including Atlas Venture, F-Prime Capital, and GV (formerly Google Ventures). The company is led by CEO Paul Wotton, who has over 25 years of experience in the biotechnology industry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!